Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA Aims To Rebuild Its Science Reputation, Plans New Projects

This article was originally published in The Pink Sheet Daily

Executive Summary

Seven priority areas include rapid detection of contaminants, adverse event detection and analysis, biomarkers, and clinical trial design and analysis.

You may also be interested in...



People In Brief

Peer Portner: The pioneer of the first electrical left ventricular assist device died Feb. 9, from cancer. Peer Portner, a Ph.D. trained in nuclear physics, lead a multidisciplinary team at Stanford University in the 1970s to develop the Novacor LVAD, used in the first bridge-to-transplant procedure in 1984. Portner also founded Novacor Medical, which was acquired by Baxter Healthcare in 1988. WorldHeart acquired the Novacor technology in 2000 and continues to market, on a limited basis, an updated version of the product as a bridge-to-transplant pump, and, in Europe, as a longer-term destination therapy

FDA Scientific Capacity Inadequate; New Device Technology At Risk

CDRH is not equipped to understand the science behind many cutting-edge device technologies, says a Nov. 29 report from the Subcommittee on Science and Technology, an ad hoc panel of the FDA Science Board

Industry Involvement In Guidance Development Encouraged By FDA Working Group

In a report on best practices for guidance development, FDA encourages outside groups to submit their own draft guidance proposals to help make the overall process more efficient.

Topics

UsernamePublicRestriction

Register

PS069151

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel